Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz et al. · New England Journal of Medicine · 2013 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

Emmanuel Beillard, Niels Pallisgaard, Vincent H. J. van der Velden et al. · Leukemia · 2003 · 884 citations

Medicine, Molecular Biology, Oncology +16

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Susan Branford, Zbigniew Rudzki, Sonya Walsh et al. · Blood · 2003 · 771 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +9

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

Anthony V. Moorman, Christine J. Harrison, Georgina Buck et al. · Blood · 2006 · 748 citations · Full text

Life Sciences, Hematology, Oncology +14

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Robin Foà, Antonella Vitale, Marco Vignetti et al. · Blood · 2011 · 461 citations · Full text

Medicine, Hematology, Oncology +12